Home › Diffuse Large B-Cell Lymphoma › District of Columbia › Washington
Diffuse Large B-Cell Lymphoma clinical trials in Washington, DC
12 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- MedStar Georgetown University Hospital, Washington D.C.
- The Center for Cancer and Blood Disorders, Bethesda · 7 mi away
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RecruitingPhase 2
- Walter Reed National Military Medical Center, Bethesda · 7 mi away
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- American Oncology Partners of Maryland Pa, Bethesda · 7 mi away
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- American Oncology Partners, P.A. ( Site 0185), Bethesda · 7 mi away
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- Georgetown University Medical Center ( Site 0117), Washington D.C.
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RecruitingPhase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RecruitingPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- Medstar Georgetown University Hospital, Washington D.C.
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- MedStar Georgetown University Hospital, Washington D.C.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- National Institute of Health, Bethesda · 7 mi away
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Houston, TX17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Portland, OR15 studies
- Nashville, TN15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Dallas, TX13 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease29 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Lymphoma23 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.